RTP Mobile Logo
Melanoma Update, Issue 1, 2008
Released August 2008

Featuring interviews with Drs Keith Flaherty and John Kirkwood. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    The incidence of melanoma continues to increase significantly, and it occurs in younger patients relative to other malignancies. Melanoma is also increasing more rapidly in men than any other malignancy, and in women it is developing more rapidly than all other types of cancer with the exception of lung cancer. In 2008, approximately 62,500 new cases will be diagnosed in the United States and 8,500 patients will die from the disease. That said, these figures are likely underestimates, as superficial and in situ melanomas are often treated on an outpatient basis and are not reported. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of advances in the diagnosis and treatment of this disease. To bridge the gap between research and practice, this issue of Melanoma Update features one-on-one discussions with leading oncology investigators Drs Keith T Flaherty and John M Kirkwood. By including information on the latest research developments and expert perspectives, this activity assists clinicians with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Critically evaluate the implications of emerging research findings on the systemic treatment of melanoma, and incorporate these data into management strategies in the metastatic setting.
    • Discuss the current placement of interleukin and interferon in the melanoma treatment algorithm, and contrast the tolerability profiles of these immunologic agents with cytotoxic chemotherapy.
    • Assess the benefits and risks of evidence-based chemotherapeutics utilized in the management of melanoma, and use this information to develop individualized treatment strategies for patients with advanced disease.
    • Consider the oncogenic mutations that play an important role in the etiology and pathogenesis of melanoma when formulating treatment strategies using biologic therapies.
    • Provide a summary of the scientific rationale and recent research results that support the early activity of novel chemotherapeutic agents, CTLA4-blocking antibodies, multikinase inhibitors and VEGF inhibitors in patients with melanoma, and appraise their future clinical applicability.
    • Counsel appropriately selected patients with melanoma about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s. 

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Love had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Flaherty Advisory Committee: Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Centocor Ortho Biotech Services, Onyx Pharmaceuticals Inc, Pfizer Inc, Pharmion Corporation, Schering-Plough Corporation, Wyeth; Speakers Bureau: Wyeth. Dr Kirkwood Advisory Committee: GlaxoSmithKline, Pfizer Inc, Schering-Plough Corporation; Paid Research: Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Schering-Plough Corporation; Speakers Bureau: Schering-Plough Corporation.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Abraxis BioScience, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, GlaxoSmithKline and Synta Pharmaceuticals Corp.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2008
    Expiration date: August 2009

Acknowledge and close

Melanoma Update, Issue 1, 2008
Released August 2008

Featuring interviews with Drs Keith Flaherty and John Kirkwood. (Audio Content)